SAB Biotherapeutics Inc Total Assets
SAB Biotherapeutics Inc total assets. Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) holds total assets worth $238.21 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SABS stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of SAB Biotherapeutics Inc (2019–2025)
Total assets of SAB Biotherapeutics Inc from 2019 to 2025. This chart illustrates how SAB Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data. See SABS share price today for real-time trading data and today's change.
SAB Biotherapeutics Inc - Asset Composition Analysis
SAB Biotherapeutics Inc Total Assets Breakdown (December 2025)
SAB Biotherapeutics Inc total assets breakdown as of December 2025. SAB Biotherapeutics Inc's total assets of $238.21 Million consist of 58.5% current assets and 41.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.1% |
| Accounts Receivable | $946.78K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how SAB Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is SAB Biotherapeutics Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SAB Biotherapeutics Inc's current assets represent 58.5% of total assets in 2025, an increase from 51.6% in 2019.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2025, down from 35.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
SAB Biotherapeutics Inc Competitors by Total Assets
Key competitors of SAB Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
SAB Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.22 | 0.87 | 2.09 |
| Quick Ratio | 9.22 | 0.87 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $96.23 Million | $-1.37 Million | $11.44 Million |
SAB Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between SAB Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.45 |
| Latest Market Cap to Assets Ratio | 1.64 |
| Asset Growth Rate (YoY) | 291.0% |
| Total Assets | $172.81 Million |
| Market Capitalization | $283.88 Million USD |
Valuation Analysis
Above Book Valuation: The market values SAB Biotherapeutics Inc's assets above their book value (1.64x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: SAB Biotherapeutics Inc's assets grew by 291.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SAB Biotherapeutics Inc (2019–2025)
The table below shows the annual total assets of SAB Biotherapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $172.81 Million | +291.01% |
| 2024-12-31 | $44.20 Million | -47.35% |
| 2023-12-31 | $83.94 Million | +64.90% |
| 2022-12-31 | $50.90 Million | -37.26% |
| 2021-12-31 | $81.14 Million | +43.52% |
| 2020-12-31 | $56.54 Million | +214.04% |
| 2019-12-31 | $18.00 Million | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more